EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Brian G. Feagan  ¹     Edward V. Loftus, Jr.  ²     Silvio Danese  ³     Severine Vermeire  ⁴     William Sandborn  ⁵     Tim Ritter  ⁶     Rajiv Mehta  ⁷     Ursula Seidler  ⁸     Frank Seibold  ⁹     Ian Beales  ¹⁰     Hyo Jong Kim  ¹¹     John McNally  ¹²     Chohee Yun  ¹²     Sally Zhao  ¹²     Xiaopeng Liu  ¹²     Chantal Tasset  ¹³     Robin Besuyen  ¹⁴     Mamoru Watanabe  ¹⁵     Stefan Schreiber  ¹⁶     Gerhard Rogler  ¹⁷     Toshifumi Hibi  ¹⁸     Laurent Peyrin-Biroulet  ^19    
1 Western University, London, Canada
² Mayo Clinic College of Medicine, Rochester, United States
³ Humanitas University, Milan, Italy
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ University of California San Diego, La Jolla, United States
⁶ GI Alliance, Southlake, United States
⁷ Surat Institute of Digestive Science (SIDS), Surat, India
⁸ Hannover Medical School, Hannover, Germany
⁹ Seibold & Partner Crohn’s Colitis Center, Bern, Switzerland
¹⁰ Norfolk and Norwich University Hospital, Norwich, United Kingdom
¹¹ Kyung Hee University Hospital, Seoul, Korea (Republic of)
¹² Gilead Sciences, Inc., Foster City, United States
¹³ Galapagos NV, Mechelen, Belgium
¹⁴ Galapagos BV, Leiden, Netherlands
¹⁵ Tokyo Medical and Dental University, Tokyo, Japan
¹⁶ University Hospital Schleswig-Holstein, Kiel, Germany
¹⁷ University Hospital of Zurich, Zurich, Switzerland
¹⁸ Kitasato University Kitasato Institute Hospital, Tokyo, Japan
¹⁹ Lorraine University, Vandoeuvre-les-Nancy, France

Topic
IBD

Session
Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)